Randomized Phase II Study of Dose-Adjusted Epoch-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics.

Trial Profile

Randomized Phase II Study of Dose-Adjusted Epoch-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 May 2017

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Feb 2017 Planned End Date changed from 1 Jun 2020 to 10 May 2020.
    • 03 Feb 2017 Planned End Date changed from 1 Jun 2020 to 10 May 2020.
    • 03 Feb 2017 Planned primary completion date changed from 1 Jun 2018 to 10 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top